NIH R01 · 2025
GLP-1R agonist immune targets in lean and obesity-associated asthma
Project Summary Multiple preclinical and clinical studies show that glucagon-like peptide-1 receptor (GLP-1R) agonists, FDA approved agents used in type 2 diabetes, obesity, and cardiovascular risk reduction, are a promising novel treatment strategy for asthma. However, the key cellular targets and mechanisms by which GLP-1R agonists reduce airway inflammation in asthma remain poorly understood. The rationale for the proposed research is that a better understanding of the cellular targets and anti-inflammatory mechanisms of GLP-1 signaling is required in order to maximize the clinical use of GLP-1R agonists for the treatment of both lean and obese patients with asthma. The overall objective…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.